Skip to main content
. 2017 Sep 6;8:465. doi: 10.1038/s41467-017-00493-9

Table 2.

The clinicopathological characteristics related to the expression of APOBEC3A in the second cohort (n = 188)

Patient categories Case No. APOBEC3A expression level p-value
Low (%) High (%)
Gender
 Male 172 87 (46.2) 85 (45.2) 0.794
 Female 16 7 (3.72) 9 (4.79)
Age a 51.2 ± 10.8 (80, 29) 52.4 ± 10.0 (79, 30) 0.327
pT status
 1–2 87 39 (20.7) 49 (26.1) 0.109
 3–4 100 56 (29.8) 44 (23.4)
pN status
 (−) 97 42 (22.3) 55 (29.2) 0.079
 ( + ) 91 52 (27.6) 39 (20.7)
Overall pathological stage
 I–II 56 19 (10.1) 37 (19.6) 0.006b
 III–IV 132 75 (39.8) 57 (30.3)
ECS c
 (–) 142 68 (36.1) 74 (39.3) 0.396
 (+) 46 26 (13.8) 20 (10.6)
Cell differentiation d
 W-D + M-D 163 78 (41.4) 85 (45.2) 0.197
 P-D 25 16 (8.5) 9 (4.7)
Perineural invasion
 No 103 44 (23.4) 59 (31.3) 0.027b
 Yes 85 50 (26.6) 35 (18.6)
Second primary occurrence
 No 174 87 (46.2) 87 (46.2) 1.000
 Yes 14 7 (3.72) 7 (3.72)
Bone invasion
 No 137 61 (32.4) 76 (40.4) 0.013b
 Yes 51 33 (17.5) 18 (9.57)
Tumor depth a 15.1 ± 10.0 (48, 1) 14.9 ± 11.1 (55, 2) 0.625

aMean ± SD, median (maximum, minimum)

bStatistically significant

cECS: extracapsular spread

dW-D: well-differentiated, M-D: moderately-differentiated, and P-D: poorly-differentiated, squamous cell carcinoma